The Netherlands
BBB Therapeutics, founded in 2003 and headquartered in The Netherlands, is a clinical stage biotechnology company that has carved a niche in developing treatments for critical brain disorders, including brain cancer and neuroinflammatory diseases.
The company leverages its proprietary G-TechnologyÂŽ platform to enhance drug delivery across the blood-brain barrier, significantly impacting how existing drugs treat neurological conditions. BBB Therapeutics currently has two key products in the clinical trial stage: 2B3-101, which is in a Phase IIa trial in both Europe and the US targeting primary brain tumors and brain metastases, and 2B3-201, intended for MS relapses and other neuroinflammatory disorders, which is completing a Phase I clinical study.
Their last known funding round was a €10.00M Series C investment on 02 July 2014. BBB Therapeutics positions itself as a key innovator in the biopharma industry, showing strong potential for future growth and clinical success.
